Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara) today announced that there were differences in the non-consolidated financial results (Japanese standard) between the fiscal year (FY) ended March 2023 (April 1, 2022 to March 31, 2023) and previous FY.

1. Differences in the full-year non-consolidated financial results between the FY ended March 2023 and the previous FY

   (Millions of yen, except basic earnings per share)

   	Sales	Operating Profit	Ordinary Profit	Net Profit for the year	Basic earnings per share（yen）
   Previous Results(A) (FY ended March 2022)	357,023	119,899	121,057	94,594	190.51
   Actual Results(B) (FY ended March 2023)	441,242	152,004	150,755	117,190	239.96
   Change（B－A）	84,219	32,105	29,699	22,596	-
   Change（％）	23.6	26.8	24.5	23.9	-

2. Reasons for the differences
   Because of the growth in sales of main products such as “Opdivo Intravenous Infusion” for malignant tumors, and “Forxiga Tablets” for diabetes, chronic heart failure and chronic kidney disease, etc., as well as an increase in royalty revenue, there were differences in the full-year non-consolidated financial results between the FY ended March 31, 2023 and the previous FY.